A number of healthcare stocks fell in the afternoon session after several negative developments weighed on the sector.

The significant downgrade comes as UBS revised its earnings per share estimates for Centene, projecting a 55% decline to $3.25 for 2025 and a 45% decline to $4.50 for 2026.

After its stock price closed at $56.65 on Tuesday, Centene announced that afternoon it was scrapping its 2025 guidance, triggering an after-hours sell off.

The $28.19 billion healthcare provider, currently trading near its 52-week low, appears undervalued according to InvestingPro analysis. The significant downgrade comes as UBS revised its earnings per ...

A class action securities lawsuit was filed against Centene Corporation that seeks to recover losses of shareholders who were adversely affected by alleged securities fraud between December 12, 2024 ...

After its stock price closed at $56.65 on Tuesday, Centene announced that afternoon it was scrapping its 2025 guidance, triggering an after-hours sell off.

On this news, Centene's stock price fell $22.87, or 40.4%, to close at $33.78 per share on July 2, 2025, thereby injuring invetors. What Is The Lawsuit About?

UBS downgraded Centene’s stock from Buy to Neutral, citing the company’s withdrawal of guidance and concerns over earnings. The firm projects a significant decline in Centene’s earnings per ...

A number of healthcare stocks fell in the afternoon session after several negative developments weighed on the sector.

The lawsuit seeks to recover losses on behalf of Centene investors who were adversely affected by alleged securities fraud ...

The Law Offices of Frank R. Cruz announces that a class action lawsuit has been filed on behalf of investors who purchased Centene Corporation ("Centene" or the "Company") (NYSE: CNC) securities ...

UnitedHealth, Centene, and Elevance suffered steep market cap losses amid earnings guidance withdrawals and potential Medicaid changes tied to new legislation.